Tumor beta2-microglobulin and HLA-A expression is increased by immunotherapy and can predict response to CIT in association with other biomarkers
BackgroundDownregulation of MHC class I expression and/or defects in the antigen presentation pathways are commonly reported in human cancers. Numerous studies previously have explored extensively the molecular mechanisms that underlie HLA-class I and Beta2-Microglobulin (B2M) downregulation. Howeve...
| Main Authors: | , , , , , , |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
Frontiers Media S.A.
2024-02-01
|
| 叢編: | Frontiers in Immunology |
| 主題: | |
| 在線閱讀: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1285049/full |